

Shruti Bhatt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3649047/publications.pdf>

Version: 2024-02-01

38
papers

936
citations

567281

15
h-index

677142

22
g-index

39
all docs

39
docs citations

39
times ranked

2005
citing authors

#	ARTICLE	IF	CITATIONS
1	PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. <i>Blood</i> , 2018, 132, 1095-1105.	1.4	160
2	Inhibition of USP10 induces degradation of oncogenic FLT3. <i>Nature Chemical Biology</i> , 2017, 13, 1207-1215.	8.0	89
3	CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. <i>Blood</i> , 2013, 122, 1233-1242.	1.4	82
4	Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2020, 38, 872-890.e6.	16.8	80
5	Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13069-13074.	7.1	79
6	miR-155 regulates HGAL expression and increases lymphoma cell motility. <i>Blood</i> , 2012, 119, 513-520.	1.4	74
7	Statins enhance efficacy of venetoclax in blood cancers. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	61
8	Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma. <i>Journal of Clinical Investigation</i> , 2013, 123, 2616-2628.	8.2	59
9	Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. <i>Blood</i> , 2019, 134, 160-170.	1.4	41
10	Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma. <i>Blood</i> , 2012, 119, 5478-5491.	1.4	39
11	miR-181a negatively regulates NF- κ B signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis. <i>Blood</i> , 2016, 127, 2856-2866.	1.4	37
12	Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma. <i>Blood</i> , 2015, 126, 1555-1564.	1.4	31
13	Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity. <i>Blood</i> , 2017, 129, 2246-2256.	1.4	23
14	Interleukin 21 – its potential role in the therapy of B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2017, 58, 17-29.	1.3	20
15	<i>Chlamydomonas reinhardtii</i> -negative ocular adnexal marginal zone lymphomas express self polyreactive B-cell receptors. <i>Leukemia</i> , 2015, 29, 1587-1599.	7.2	17
16	Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 128, 239-248.	1.4	17
17	Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy. <i>American Journal of Hematology</i> , 2020, 95, 245-250.	4.1	13
18	Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma. <i>Leukemia</i> , 2022, 36, 1088-1101.	7.2	6

#	ARTICLE	IF	CITATIONS
19	Targeting B-Cell Malignancies With Anti-CD20-Interleukin-21 Fusokine. Blood, 2013, 122, 377-377.	1.4	3
20	Preclinical Activity of Brentuximab Vedotin (SGN-35) in Primary Effusion Lymphoma (PEL). Blood, 2011, 118, 3728-3728.	1.4	2
21	Dynamic BH3 profiling method for rapid identification of active therapy in BH3 mimetics resistant xenograft mouse models. STAR Protocols, 2021, 2, 100461.	1.2	1
22	Interleukin-21 Potently Induces Direct and Indirect Cytotoxicity of Mantle Cell Lymphoma. Blood, 2014, 124, 1776-1776.	1.4	1
23	Dynamic BH3 Profiling Predicts for Clinical Response to Lenalidomide Plus Chemotherapy in Relapsed Acute Myeloid Leukemia. Blood, 2018, 132, 4058-4058.	1.4	1
24	Identification of LMO2 Transcriptome and Interactome in Diffuse Large B-Cell Lymphoma by Integrated Experimental and Computational Approach. Blood, 2011, 118, 438-438.	1.4	0
25	Synergistic Preclinical Activity of Bortezomib with Suberoylanilide Hydroxamic Acid (SAHA) in Primary Effusion Lymphoma (PEL). Blood, 2011, 118, 1650-1650.	1.4	0
26	Abstract LB-328: Preclinical activity of interleukin 21 in mantle cell lymphoma.. , 2013, , .		0
27	B Cell Receptors Of Chlamydomonas reinhardtii negative MALT Lymphomas Of The Ocular Adnexa Recognize Common Self-Antigens. Blood, 2013, 122, 4266-4266.	1.4	0
28	Germinal Center Kinase Regulates The Proliferation and Survival Of Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 643-643.	1.4	0
29	Mirna-181a expression Lead to Longer Animal Survival and Slower Tumor-Growth Rate in Diffuse Large B-Cell Lymphoma Xenograft Models. Blood, 2014, 124, 2963-2963.	1.4	0
30	Abstract 418: Mitochondrial perturbations as a novel approach to personalized medicine. , 2016, , .		0
31	FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML). Blood, 2016, 128, 1681-1681.	1.4	0
32	Statins Potentiate the Cytotoxic Effect of ABT-199 in Diffuse Large B Cell Lymphoma. Blood, 2016, 128, 3969-3969.	1.4	0
33	A Functional Approach to Precision Medicine Identifies Targeted Therapies for Acute Myeloid Leukemia. Blood, 2017, 130, 853-853.	1.4	0
34	Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML). Blood, 2018, 132, 3895-3895.	1.4	0
35	Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia. Blood, 2019, 134, 2551-2551.	1.4	0
36	Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL. Blood, 2019, 134, 3948-3948.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Pre-Clinical Validation of a Novel Erk1/2 and CDK4/6 Inhibitor Combination in Multiple Myeloma (MM). Blood, 2020, 136, 22-23.	1.4	0
38	Abstract 2990: Individualized functional approach to tailoring acute myeloid leukemia therapy. , 2019, , .		0